Factors influencing malignant evolution and long-term survival in solitary fibrous tumours of the pleura by Rodríguez-González, Marta et al.
Summary. Solitary pleuro-pulmonary fibrous tumours
are relatively uncommon neoplasms that are difficult to
manage therapeutically and which, cytogenetically, have
been poorly studied. 
The aim of the present work was to analyse the
characteristics of a series of consecutive operated
solitary pleural fibrous tumours in an attempt to discover
a malignant pattern of evolution.
This was a retrospective observational study of 19
cases. Samples were studied for clinical, histological,
immunohistochemical and cytogenetic characteristics
(aCGH, FISH). Descriptive statistics were used: the
Kapplan-Meyer log-rank test and the Cox-regression
model for survival analysis. Analysis of malignant
evolution was achieved using 2x2 tables; significant
factors were included in a binary logistic regression
model. 
Parietal pleural implantation of the primary tumour,
high mib1 expression, and low p53 expression were seen
to be statistically significant factors for survival. We
recommend a close follow-up for patients with a
malignant primary tumour and low p53 expression and a
regular long-term follow-up for benign primary tumours
with a high mib1 index, high positive p53, and deletions.
These findings need confirmation in more extensive
series.
Key words: Solitary pleural fibrous tumour, Malignant
pleural tumour, MIB-1 index prognostic value, Genetic
analysis, aCGH and FISH analysis
Introduction
Solitary pleural fibrous tumours (SPFT) are
infrequent mesenchymal neoplasms and account for 5
and 10% of all pleural tumours (Cardillo et al., 2009;
Park et al., 2011). First described by Klemperer and
Rabin in 1931 (England et al., 1989), around 1000 cases
have been reported in the literature. Their histogenesis is
unknown and bears no relationship to exposure to
asbestos or smoking. They are often detected in routine
diagnoses for check-ups or other causes, in which about
50% of patients are asymptomatic. Complete surgical
resection is the treatment of choice, followed or not by
adjuvant radiotherapy.
Macroscopically, an SPFT is a non-encapsulated
well-circumscribed mass, pedunculated or sessile. SPFTs
have multiple microscopic growth patterns, which can be
classified as solid-spindle or diffuse-sclerosing (Moran
et al.,1992; Zhang et al., 2004). Although the
histogenesis of such tumours is unknown, protein
expression is characteristically positive for vimentin,
CD34 and bcl2, and is negative for cytokeratins (CKs).
Some authors have linked the expression of p53 and
ki67 (mib1) to a high degree of aggressiveness (Park et
al., 2011).
Few cytogenetic analyses of SPFT have been
reported (Fletcher, 1997; Torabi et al., 2008; Swelam et
al., 2009; Torres-Olivera et al., 2009) and they have
proved to be poorly consistent, with controversial
results, because they are based on studies of short series
or isolated cases (Schirosi et al., 2008). In the cases that
have been reported (Mitelman Database of Chromosome
Aberrations and Gene Fusions in Cancer, 2012), no
consistent cytogenetic abnormalities were detected.
Factors influencing malignant evolution and long-term
survival in solitary fibrous tumours of the pleura
Marta Rodríguez-González1, Nuria M. Novoa2, Maria T. Gomez3, J.L. García4 and Dolores Ludeña5
1Pathology Department. University Hospital of Salamanca, 2Thoracic Surgery Department.-Institute of Biomedical Research of
Salamanca (IBSAL), 3Thoracic Surgery Department. University Hospital of Salamanca, 4Research Unit of the University Hospital of
Salamanca, Spain-Centre for Cancer Research, Salamanca (CIC IBMCC-CSIC/USAL) and 5Pathology Department. University
Hospital of Salamanca, Spain-Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
Histol Histopathol (2014) 29: 000-000
Offprint requests to: Marta Rodríguez-González, Pathology Department,
University Hospital of Salamanca, Salamanca, Spain. e-mail:
marta_rg@usal.es
http://www.hh.um.es
Histology and
Histopathology
Cellular and Molecular Biology
Thus, it seems that knowledge of the cytogenetics and
genomic changes occurring in SPFTs could be important
to determine the pathogenesis of this type of neoplasm
and its treatment using new therapeutic targets.
Most of these tumours show a biologically benign
behaviour, although up to 30% of them eventually show
local relapses and as many as 12% display malignant
behaviour (Abu Arab, 2012). Despite the different
classifications proposed (England et al., 1989; de Perrot
et al., 2002), no definitive clinical, histological,
immunohistological or genomic criteria have been
reported to attempt to classify patients who will develop
a malignant pattern.
The aim of the present work was to analyze the
clinical, histological, immunohistochemical and
cytogenetic characteristics of a series of consecutive
pleural fibrous tumours operated at a tertiary hospital
with the aim of discovering a malignant pattern of
evolution so that close monitoring can be offered to
patients at risk.
Material and methods
This was a retrospective observational study based
on a series of SPFTs operated between July 1995 and
March 2011 at the University Hospital of Salamanca,
Spain. All clinical variables and outcomes used in this
analysis were recorded prospectively on a customized
database.
The series comprised 19 operated patients and these
afforded a total of 23 samples to study: 19 primary
tumours and 4 relapses. All cases were fixed in 10%
formalin-buffer and embedded in paraffin. In order to
obtain robust specimens for tissue-array composition, a
careful selection of the most representative areas was
performed in triplicate by a senior consulting
pathologist. Histological and immunohistochemical
analyses were performed in all specimens. In 21 samples
from 19 tumours DNA was collected for cytogenetic
studies.
The following variables belonging to different areas
were recorded for study:
1.-Clinical variables: age, sex, presenting symptoms,
number and description of surgical procedures, death
due to tumour relapse.
2.-Histological variables: size, position of
implantation on the pleura, sessile or pedunculated, a
benign or malignant diagnosis, and the de Perrot
classification of the tumours (de Perrot et al., 2002).
3.-Immunohistochemical variables: presence or lack
of expression of CKs, vimentin, CD34, CD99, ALK,
Calretinin, S100, actin, bcl 6, bcl 2 and the degree of
expression of mib1, p53, PDGFR α and PDGFR ß. p53
expression was considered positive when at least 5% of
the cells reacted with the specific antibody with an
intensity of 2+. The intensity of expression of mib1
(ki67) was classified as 0 (negative) when less than of
5% of the cells reacted with the specific antibody; as 1
(low) when the reaction was seen in 5-20% of the cells,
and as 2 (high) when it was seen in more than 20% of
the cell population. The PDGFR index (for α and ß
receptors) was calculated after measuring the intensity of
expression (0 low, 1 medium, 2 high) and the percentage
of cells that reacted with the specific antibody. The other
antibodies were considered positive when 5% or more of
the tumour cells reacted with the specific antibody.
4.-Genetic variables: genomic changes observed as
gains and/or losses of DNA, identifying copy-number
alterations (CNAs) and FISH values.
5.-Patient status: the final status of all patients was
determined in December 2011 on the basis of either the
patient’s most recent clinical visit or hospitalization or
by means of a telephone interview.
DNA isolation
Genomic DNA was extracted from FFPET samples
in which at least 70% of the cells visible in the section
were tumour cells. Tissue sections (3 µm) were
deparaffinized. DNA was quantified using a Nanodrop
spectrophotometer (ND-1000, NanoDrop Technologies,
Wilmington, DE, USA) and its quality was assessed by
the 260:280 ratio and by agarose gel visualization.
Comparative genomic hybridisation study
Comparative Genomic Hybridisation (CGH) was
performed using oligonucleotide microarrays (Roche
NimbleGen, Inc., Reykjavik, Iceland) in order to identify
CNAs. The whole genome oligonucleotide microarray
was provided by NimbleGen. 1 µg gDNA from each
FFPE sample and reference sample was labelled using
the NimbleGen. Dual-Color DNA Labeling Kit and
hybridized to a NimbleGen Human CGH 12x135K.
Sample preparations and hybridizations were carried out
according to the manufacturer's protocols (NimbleGen
Arrays User's Guide-CGH Analysis, Roche NimbleGen,
Inc.).
Data analysis
Raw data on fluorescence intensity were obtained
from scanned images of the oligonucleotide arrays, using
NIMBLESCAN 2.3 extraction software (NimbleGen
Systems). The data were normalized and analyzed using
the segMNT algorithm in NimbleScan v2.6 Software.
Additionally, we used the CGHweb interface, which
generates a heatmap panel of the segmented profiles
according to the different methods used, as well as a
consensus profile (Lai et al., 2008).
Fluorescence in situ hybridization (FISH)
Interphase FISH was performed on all the samples
using commercially available probes with the LSI
22q11.2 (DiGeorge Sind/ VCFS Dual Color), LSI c-myc
(8q24.12-q241.3) Spectrum Orange and CEP3, CE7,
CEP 17 and LSI 9p2 and the LSI p53 (17p13). We used
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cosmid 9-4 and 4-1 to test for the PDGFR ß gene in the
5q31-33 region as well as probes for the PDGFR
α/FIP1L1 fusion (these probes were kindly provided by
Professor P. Marynen, Centre for Human Genetics,
Leuven, Belgium). Interphase FISH used the method
described previously (Robledo et al., 2009). FISH
signals in morphologically intact, non-overlapping
nuclei were counted. The images were captured on an
Olympus BX60 epifluorescence microscope coupled
with a CCD camera and then evaluated with Cytovision
software (Applied Imaging). Approximately 400 non-
overlapping tumour cells were evaluated.
Statistical analysis
Descriptive analyses of the main patient
characteristics, their clinical symptoms, and the
macroscopic features of the tumours and relapses are
reported. Categorical data are presented using the
number of cases and (%); continuous normally
distributed data are expressed as means ± SD, while
continuous non-normally distributed data are presented
as medians (range).
Univariate analysis of survival probability was
calculated with the Kaplan-Meier method, using the log-
rank test to analyze differences between groups. Then, a
multivariate Cox regression model was implemented,
including significant variables in the previous univariate
analyses to identify any adverse prognostic factors.
The relationship between variables and a malignant
pattern of evolution was analyzed using comparative
tests to calculate the odds ratio and its 95% confidence
interval. If a positive relationship was found, a binary
logistic regression model was developed using the
statistically significant variables. P<0.05 was considered
significant.
All calculations were performed with SPSS-15 for
Windows.
Results
Clinical data
19 patients were operated. Most of them were
female (13 out of 19) and the mean age of the series was
57.4±14.6 years (range: 34-78 years). In 6 cases (31.2%)
the primary tumour was discovered due to thoracic pain
but in 5 (26.3%) it was asymptomatic and was
discovered by chance in a radiological study. In 4
patients (21.1%) dyspnoea and in 2 cases (10.5%) cough
were the reasons for consulting. Two patients had
paraneoplastic syndromes: one had recurrent
hypoglycaemia and other hypertrophic pulmonary
osteoarthropathy.
The mean size of the primary tumours was
12.57cm±5.5 (range: 3-22cm). Most tumours were
pedunculated and had grown from the visceral pleura.
84.2% of the primary tumours were benign and 52.6%
were classified as stage 0 of the de Perrot classification
(Table1). Only in one case, case 11, did the tumour
appear as multiple benign lesions growing from the
visceral pleura of the left inferior pulmonary lobe. It
consisted of a large central mass 7 cm in diameter and
two smaller satellite nodules. In this initial surgery, the
procedures varied from simple resection of the tumour (7
cases) to extrapleural right pneumonectomy with
replacement of the pericardium and diaphragm. In all
cases, surgery was considered macroscopically and
microscopically complete because no positive margins
were observed in the final pathological reports. The
mortality of the series at 30 days was zero.
Six cases had a tumour relapse. In 2 cases, an
extensive local and distant relapse plus a poor general
situation precluded surgery and both died due to
progression of the illness at two and three years after the
first surgical intervention respectively. A further 2 cases,
in which a first local relapse was operated, currently
have extensive local non-surgically treatable relapses
and are receiving chemotherapy. Finally, one malignant
3
Solitary fibrous tumours of the pleura
Table 1. Summary of macroscopic and microscopic characteristics of
the primary tumors.
n=19
Localization Visceral pleura 12
Parietal pleura 2
Mediastinic pleura 4
Multiple 1
Implantation type Pedunculated 13
Sessile 6
Histology Benign 16
Malignant 3
de Perrot’s stages 0 10
1 6
2 2
3 1
4 0
Table 2. Inmunohistochemical characteristics of the tumors.
Nº %
P53 Positive 15 78.9
Negative 4 21.1
Mib1 <5% 12 63.1
5-20% 3 15.8
>20% 4 21.1
Bcl 6 Positive 8 42.9
Negative 11 57.1
Mean Range
PDGFRα 0.24±0.4 0-1.6
PDGFRß 0.35±0.5 0-1.6
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Fig. 1 A. External surface of a solitary pleural fibrous tumour (SPFT), a non-encapsulated well-circumscribed and consistently firm mass. B. Cut
surface of a SPFT with a lobulated appearance. C. Histology of a benign. D. Histology of a malignant SPFT, displaying increased cellularity and
atypical features (Hematoxilin-eosin). E. Malignant SPFT immunostained for mib1 (immunohistochemistry for mib1). F. High p53 index in a malignant
SPFT (Immunohistochemistry for p53). Scale bar 50 µm.
and one benign case of relapse were operated and the
patients are currently free of illness at one and four years
after the second surgery, respectively.
The mean size of the relapsed tumours was 7.9±3.7
cm (range: 5-14). Most were sessile (3 out of 4) and
multiple (4 out of 6), 2 cases having local and
extrapleural tumors: one in the chest wall and the other
in the abdominal wall. All but one were classified as
stage 3 or 4 of de Perrot’s classification. The surgical
procedures in this group (4 cases) were more complex
than in the first operation, requiring different degrees of
lung resection and adjacent tissue removal to guarantee
complete surgical excision of the lesions. The mortality
of the second procedures was zero.
Morphological and immunohistochemical data (Table 2).
Macroscopically, most of the tumours were well-
delimited, had a consistent firmness and were lobulated
in section (Fig. 1a,b). 16 of the primary tumours and
only 1 of the relapses were classified as histologically
benign (England et al., 1989). The others, 3 primary
tumours and 3 relapses, were classified as malignant
(England et al., 1989) (Fig. 1d). 81% of the tumours
were predominantly cellular and only in 2 cases was the
stroma predominant (Zhang et al., 2004). The most
frequent clinical picture was the “paternless pattern”,
observed in 14 specimens, followed by the
haemangiopericytoma-like pattern (Fig. 1c). 
All tumours displayed a homogeneous
immunoexpression of CD34, Bcl2, vimentin and no
expression of cytokeratin, CD99, calretinin or ALK. p53
showed a positive expression in 78.9% of the primary
tumours (15 specimens) and in all relapses (Fig. 1f).
Mib1 expression in the primary tumours was 0
(negative) in 12 cases, 1 (low) in 3 cases, and 2 (high) in
4 cases (Fig. 1e); while it was variable in the relapses.
PDGFR analysis in the group of primary tumours
revealed that 7 patients had a negative Haura Index (HI)
(Haura et al., 2005) for PDFGRα and 6 cases were HI-
negative for PDFGRß. By contrast, 1 case of PDFGRα
and 2 cases of PDFGRß had a high index of 1.6. The
distribution of the values for PDFGRα had a mean of
0.24±0.4 (range 0-1.6) while for PDFGRß the mean was
0.35±0.5 (range: 0-1.6).
FISH and aCGH data
To identify sites of CNAs, aCGH was performed. In
37% of cases (7/19) we observed genomic changes.
Losses were more frequent than gains (27 vs. 16). The
most frequent losses were seen for 1p34.2 and 8p23.3 in
3/7 cases and 7q21 in 2/7 cases (Table 3).
According to the FISH analyses, 3 of 15 cases
presented trisomy for LSI C-Myc in 40%, 30% and 30%
of the cells. In most cases no aberrations were revealed
by FISH on chromosomes 3, 7, 17, 9p21 and 22q11. Two
cases showed trisomy 3 in 30% of cells and only one
case showed + 7 (Fig. 2). We did not identify any
patients with rearrangement on 4q12 or 5q31-q33. In
two cases, the deletion of p53 was observed in 38% and
44% of the nuclei.
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Fig. 2. Paraffin section interphase FISH. FISH performed on a paraffin-
embedded tissue section of an SPFT with probes for the centromeric
region of chromosome 3 CEP 3 (orange signals) and 7 (green signals).
10x1000
Fig. 3. Survival curves showing the influence of the diagnosis of
malignancy of the primary tumour on tumour-related survival.
Survival data
At the time of the present analysis, only two patients
had died of tumour progression; another one died of an
unrelated cause; two are currently receiving
chemotherapy treatment, and the rest are alive and free
of illness. The global follow-up period of the series is 17
years and 3 months, and the mean follow-up is
59.4±58.4 range (3-185) months.
The median survival time of the series has not been
reached yet, and the mean survival time is 155.7±18.6
months (95IC%: 119.1-192.3). The median disease-free
interval of the cases that underwent a relapse is 17±14
months, in contrast to a disease-free interval of 120±54
months of the rest of the series. Histological
classification as benign or malignant (p=0.001) (Figure
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Fig. 5. Influence of p53 expression on cumulative survival. Survival is
reduced in non-p53-expressing tumours.
Fig. 4. Survival curves showing the influence of parietal implantation of
the primary tumour on survival.
Table 4. Binary logistic model for recurrence.
Variable Wald Significance ß ß95%CI
Parietal pleura implant 6.17 0.013 0.46 0.004-0.52
MIB1 expression 4.42 0.035 9.02 1.16-70.02
Table 3. Cases with genimoc changes detected by aCGH.
Case number Losses Gains
1
2
3
4 1p34.2
5
6
7 1p13.3 2q32.1
7q21.11 9q21.33
7q33 10p14
8p23.3 15q25.1
16q22.3 15q26.1
19p13.2 18q22.3
22q12.3-q13.1
8 1p34.3-p34.2 2q37.3
2p25.1 11q12.1
2p24.1 13q12.11-q12.12
2p11.2 20q13.33
2q11.1-q11.2
2q37.2
3p25.1
3p14.2
4q35.1
7q21.12-q21.13
13q14.2
14q31.1
9
10
11
12 4q28.3
13 7p15.1 3q25.3
8p23.3-p23.1 4p11-q11
15q25.2 13q14.3
17p12 17p13.1
17q11-1-q11.2
14
15
16
17 1p34.2
18
19 8p23.3
12q24.32
3), parietal pleural implantation of the primary tumour
(p=0.001) (Fig. 4), minimum/negative p53 expression
(Fig. 5) and mib1 high expression (p=0.003) (Fig. 6)
were significant factors for survival in the univariate
analysis; these were not supported in the multivariate
analysis owing to the small sample size and the short
number of tumour-related deaths that had occurred.
No relationship was found between survival and the
rest of the variables recorded: clinical, histological,
immunohistochemical or other cytogenetic alterations. 
Relationship to malignant evolution
All variables were tested again to attempt to find a
common pattern for predicting a malignant evolution of
the primary lesion, defined as the occurrence of relapse.
In an individual analysis, the following variables showed
a statistically significant relationship with recurrence:
parietal pleural implantation of the primary tumour
(c2=4.84; bilateral p=0.02; OR: 0.235 95%CI (0.1-
0.554)) and high expression of mib1 (Χ2=14.7; bilateral
p=0.001; OR: 6 95%CI (1.03-35.9). In the binary
logistic regression, both variables maintained their
statistical significance (Table 4).
Even though we only found a statistical relationship
of the probability of recurrence with the parietal position
of the primary tumour and a high mib1 expression, when
the cases were ordered according to the histology of the
primary tumour and the final occurrence of relapse an
almost homogeneous pattern appeared (Table 5).
According to this table, it seems that patients with a
benign primary tumour showing a medium-high mib1
expression, a high positive p53 expression and the
presence of cytogenetic losses have a higher risk of
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Fig. 6. Survival curves showing the influence of mib1 expression.
Survival is decreased in high mib1-expressing cases.
Table 5. Tidied cases according to the primary tumour histology and the occurrence of relapse.
Case number Histology of de Perrot’s stage Location Histology of Gene Losses Mib 1 P53 Deaths
primary tumor relapses >0’6 MB index index
1 Benign 1 Visceral pl. - - 5% 20% -
4 Benign 0 Visceral pl. - + 5% 5% -
5 Benign 0 Visceral pl. - - 5% 50% -
6 Benign 1 Visceral pl. - - 5% 60% -
7 Benign 0 Visceral pl. - + 5% 50% -
8 Benign 0 Visceral pl. - + 5% 60% -
12 Benign 1 Visceral pl. - - 5% 50% -
13 Benign 1 Visceral pl. - + 5% 5% -
14 Benign 0 Mediastinum - - 5% 20% -
16 Benign 0 Mediastinum - - 5% 30% -
17 Benign 0 Visceral pl. - + 5% 20% -
18 Benign 1 Visceral pl. - - 5% 25% -
3 Benign 0 Visceral pl. Benign - 10% 30% -
9 Benign 0 Mediastinum Malignant + 10% 50% -
11 Benign 1 Multiple Malignant - 10% 50% -
19 Benign 0 Parietal pl. Malignant + 20% 30% -
2 Malignant 2 Parietal pl. Malignant - 20% 5% +
10 Malignant 2 Parietal pl. Malignant - 40% 5% +
15 Malignant 3 Visceral pl. - - 10% 20% -
recurrence as a group (c2=10.3; bilateral p=0.005; OR:
0.14 95%CI (0.040-0.515)).
Discussion
SPFT is an infrequent lesion and at our Hospital we
have seen only 23 cases in the last 16 years. Consistent
with reports in the literature, most of them were benign.
However, the behaviour of these tumours is still difficult
to predict, and hence, long-term follow-up is
recommended (de Perrot et al., 2002; Schirosi et al.,
2008).
In consonance with the literature reviewed (Swelam
et al., 2009), we found that primary parietal pleural
implantation of the tumour is a very negative factor for
survival. In our results, this was one of the most
significant prognostic factors since it revealed the
statistically significant influence on survival and on the
probability of recurrence. According to the data shown
in table 5, the power of this variable is related to the two
deceased malignant cases whose original tumours were
in this position and to case number 19, in which the
benign primary lesion recurred later on, in contrast to the
rest of the series. Upon analyzing our series, we detected
two distant metastases without local relapse, which is an
uncommon finding. This has been addressed previously
by Cardillo et al. (2012), who reported that the majority
of relapses occur locally. 
We consider that both the definition of the criteria of
malignancy proposed by England et al. (1989) and the
classification system of de Perrot et al. (de Perrot et al.,
2002) are useful for pathologists and clinicians. In their
review, Cardillo et al. (2012) found that sessile
malignant tumours had a poor prognosis although long
term survival was also possible. In our series most of the
cases were benign, with a low de Perrot stage (Table 1).
Although it was surprising that all the malignant first-
resected tumours showed a low de Perrot stage, the
medium survival time of the patients with those
malignant tumours was only 24 months. The malignant
potential may have masked any other possible
prognostic factors.
The reviews performed by Schirosi et al. (2008) and
Yokoi et al. (1998) suggested that a high mitotic index
and an overexpression of p53 are markers of a poor
prognosis, linking the latter with recurrence and
invasion. In our cases, mib1 expression lay between 5
and 20% in the patients with primary benign tumours
who relapsed (14.29%), and was higher than 20% in the
cases in which the tumours were malignant and had the
worst prognosis (23.81%) (Table 5).
In our series, p53 had a variable expression but it
was clearly overexpressed in the cases with a primary
benign histology who relapsed. In contrast, p53 was
almost negative in the two already deceased malignant
cases. These two cases showed a chromosomal deletion
of p53 in 38 and 44 % of their nuclei. The presence of
genetic losses in gliomas and lymphomas has been
related to shorter survival (Camacho et al., 2001; Burton
et al., 2002). This aggressive malignant behaviour
explains the significance of this factor as regards
survival (Fig. 3).
We were surprised by case number 3, which was a
benign tumour with a benign relapse. We speculate that
both lesions were present at the moment of surgery but
because of its tiny size one of them went unnoticed.
In a complete analysis of 26 solitary fibrous
tumours, Walters et al. (2011) found that 50% of their
cases expressed bcl6 with no rearrangement or
amplification in FISH analyses. In their series, positive
bcl6 expression was significantly more frequent in
malignant tumours as compared with benign or uncertain
SPFTs. In our series, we found no significant
relationship between bcl6 expression and a malignant
histology.
The genetic background of SPFTs is poorly known.
The data published about CGH and aCGH report
chromosomal anomalies in 42-53% of cases (Krismann
et al., 2000; Bertucci et al., 2013; Mohajeri et al., 2013).
In our study we observed that the SPFTs showed
genomic changes in 7/19 (38%) cases at the time of
diagnosis. In 3/7 (43%) cases we identified two common
deletion clusters in the 8p23.3 and 7q21.3 subbands,
which are "hot deletion regions". Deletions of 8p23.3
and 7q21 have been reported previously in tumours such
as colon, breast and urothelial carcinomas. This
observation makes these areas strong candidates for
tumour suppressor regions. 
A loss on 8p23.3 has been reported in previous
studies in colon, breast and urothelial carcinomas (Wood
et al., 2007; Cooke et al., 2008; Williams et al., 2010),
which makes it a strong candidate as a tumour
suppressor region. The genes affected by the minimum
common region of deletion, and therefore candidates, are
CLN8, C8orf61, has-mir-596 and ARHGEF10.
Functional data about ARHGEF10 (Rho guanine
nucleotide exchange factor (GEF)) support a role for it
in processes of carcinogenesis that are initiated by
extracellular stimuli that work through G protein-
coupled receptors. It activates RhoB, which is down-
regulated in many tumour types (Mazieres et al., 2004)
and is necessary for apoptosis in response to DNA
damage in transformed cells (Cooke et al., 2008).
It has been proposed that the larger the tumour, the
more frequent the CNAs, suggesting that genomic
changes may promote tumour growth. Thus, CGH
mainly reveals genomic changes in tumours larger than
10 cm (Abu Arab, 2012). In our study we found no
tumour size-related DNA copy-number changes.
To our knowledge, only 9 of pleural SPFTs have
been studied by conventional cytogenetics (England et
al., 1989). These studies have shown that t (4;15)
(q13;q26) and gains on chromosomes 8 and 21 were the
most frequent anomalies. In our cases, chromosomal
losses were more frequent than gains but, in agreement
with previous findings, we found gains in 8. We failed to
find any direct association between losses or multiple
cytogenetic changes (> 0’6 MB) and survival or relapse,
but the presence of cytogenetic losses in benign primary
tumours seems to be a factor warranting regular follow-
up. 
According to CGH analyses the samples in our
series showed no genomic changes detected by FISH of
4q12 and 5q, where the PDFGRα and PDFGRß are
located respectively, and these are target molecules for
Imatinib (Rossi et al., 2006). The literature reports one
case of an SPFT treated with this drug. Imatinib is a
tyrosine kinase inhibitor that acts on mutations of exons
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9 and 11 of the c-kit gene and also in no-D842V
mutations of PDGFRα in patients with gastrointestinal
stromal tumours (Rossi et al., 2006). It exerts a dual
activity, blocking TGFß (transforming growth factor)
and PDGFR  receptors in TPFS in vitro and in vivo
(Prunotto et al., 2009). More exhaustive knowledge of
the cytogenetic alterations of these tumours would allow
the use of drugs of proven effectiveness or the
development of new target therapies. 
The main limitation of our study is the sample size,
which may contribute to a loss of statistical significance
in multivariate tests. We have estimated that 259 patients
in each study arm would be needed to adequately assess
the influence of a high expression of mib1 on long-term
survival with a power of 90% (α error=0.05, RR=3).
Such sample sizes are hard to access given the low
incidence of SFTPs, and hence a broader sample, which
could be achieved through multicentre cooperation,
would be needed to confirm or reject our univariate
results.
Complete surgical removal is the treatment of
choice, but many patients relapse, long-term follow up
being essential. Indeed, there is a ten-year relapse in our
series after the first surgery. Nonetheless, no individual
patient displays the same behaviour and hence it is
necessary to establish criteria to allow patients with a
low risk of relapse to be distinguished from those who
need constant monitoring. The classifications made until
now, such as that of de Perrot et al. (2002) and that of
Abu Arab et al. (2012), are based on macroscopic and
microscopic criteria, and recommend long-term follow
up, with different intervals, for all patients. 
From our analysis, on considering primary benign
tumours that have been completely excised we
established two different groups featuring an opposite
behaviour of the disease based on morphological criteria
(location of implantation), on immunohistochemical data
(high mib1 expression and high p53 expression) and on
cytogenetic criteria (losses) (Table 5). Thus, patients
with a single visceral pleural implantation, a low de
Perrot stage, low mib1 immunoexpression, low p53 and
no losses of 0.6 MB or more will need few check-ups
after surgery. However, patients who show multiple or
parietal pleural implantations, mib 1>10 %, high p53
expression and cytogenetic losses would need a more
exhaustive follow up because of higher risk of
recurrence and the poorer prognosis. All malignant cases
need to be followed up closely, especially if p53 is
negative, due to the aggressiveness of the tumour.
Conclusions
To conclude, according to the results of our studies
primary tumour histology, parietal pleural implantation
of the primary tumour, high mib1 expression and low
p53 expression are statistically significant factors for
survival. Additionally, we recommend a close follow-up
of patients that present with a malignant primary tumour
with a low p53 expression and we recommend a regular
long-term follow-up for cases with completely excised
benign primary tumours with a high mib1 index, high
positive p53 expression and the deletion of 17p13. All
these findings need to be confirmed in more extensive
series.
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